Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Charles Beck

Sports Medicine Draper, UT Medical Doctor

NPI 1528124815 CMS profile 68473

96 E Kimballs Ln Ste 207, Draper, UT 84020

Open in the dashboard

General payments

$157,224

51 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Charles Beck of Draper, UT is reported in the CMS Open Payments database as having received $157,224 across 51 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $13,330 4
2024 General $13,069 4
2023 General $20,391 5
2022 General $23,457 9
2021 General $25,279 13
2020 General $26,439 8
2019 General $35,260 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Charles Beck
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Charles Beck were reported at $13,330. Among 2,404 Sports Medicine profiles paid that year, the median was $664 and the middle half received between $172 and $3,055.

Show as a table
Year Charles Beck Sports Medicine median Middle half National median
2019 $35,260 $1,176 $199–$4,249 $163
2020 $26,439 $708 $96–$2,890 $114
2021 $25,279 $1,213 $152–$3,994 $132
2022 $23,457 $1,230 $159–$3,998 $149
2023 $20,391 $584 $146–$2,836 $160
2024 $13,069 $628 $163–$3,168 $164
2025 $13,330 $664 $172–$3,055 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. DePuy Synthes Products, Inc. $156,230 28 payments
  2. Smith+Nephew, Inc. $485 7 payments
  3. Vericel Corporation $265 8 payments
  4. Medical Device Business Services, Inc. $113 1 payment
  5. Boston Scientific Corporation $56 3 payments
  6. Heron Therapeutics, Inc. $25 1 payment
  7. Bioventus LLC $23 1 payment
  8. Amgen Inc. $15 1 payment
  9. Ferring Pharmaceuticals Inc. $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $156,230 28 payments
  2. Food and Beverage $993 23 payments
Products named General payments · program years 2019–2025
  1. INTRAFIX Sports Surgical $94,886 20 payments
  2. INTRAFIX Sports Surgical $61,344 8 payments
  3. REGENETEN $178 3 payments
  4. MACI $177 4 payments
  5. NOVOSTITCH $126 1 payment
  6. HEALIX KNOTLESS PEEK $113 1 payment
  7. DYNACORD $113 1 payment
  8. Bristow Latarjet $113 1 payment
  9. BIOINTRAFIX $113 1 payment
  10. REGENETEN Shoulder $96 2 payments
  11. Other $319 13 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

51 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in Utah

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record